These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19877987)

  • 41. [Medical treatments of hyperactive child: about the new pharmaceutical forms of methylphenidate marketed in France].
    Le Heuzey MF; Vergnaud S; Mouren MC
    Arch Pediatr; 2006 Jan; 13(1):100-3. PubMed ID: 16239100
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases.
    Park-Wyllie L; van Stralen J; Castillon G; Sherman SE; Almagor D
    Clin Ther; 2017 Oct; 39(10):2006-2023. PubMed ID: 28988700
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan.
    Takahashi N; Koh T; Tominaga Y; Saito Y; Kashimoto Y; Matsumura T
    World J Biol Psychiatry; 2014 Aug; 15(6):488-98. PubMed ID: 24456065
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.
    Hammerness P; Wilens T; Mick E; Spencer T; Doyle R; McCreary M; Becker J; Biederman J
    J Pediatr; 2009 Jul; 155(1):84-9, 89.e1. PubMed ID: 19394037
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lymphomatoid drug reaction secondary to methylphenidate hydrochloride.
    Welsh JP; Ko C; Hsu WT
    Cutis; 2008 Jan; 81(1):61-4. PubMed ID: 18306850
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Resolution of methylphenidate osmotic release oral system-induced hair loss in two siblings after dose escalation.
    Ardic UA; Ercan ES
    Pediatr Int; 2017 Nov; 59(11):1217-1218. PubMed ID: 29359460
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
    Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
    Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Methylphenidate. A drug for attention deficit disorders to be used with precaution].
    Taéron C
    Rev Infirm; 2009 Jun; (151):47-9. PubMed ID: 19579855
    [No Abstract]   [Full Text] [Related]  

  • 49. Clinical and cognitive response to extended-release methylphenidate (Medikinet) in attention deficit/hyperactivity disorder: efficacy evaluation.
    Fernández-Jaén A; Fernández-Mayoralas DM; Pardos A; Calleja-Pérez B; Muñoz Jareño N
    Adv Ther; 2009 Dec; 26(12):1097-110. PubMed ID: 20082241
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy.
    Palumbo D; Spencer T; Lynch J; Co-Chien H; Faraone SV
    J Child Adolesc Psychopharmacol; 2004; 14(2):185-94. PubMed ID: 15319016
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drugs for ADHD.
    Med Lett Drugs Ther; 2020 Jan; 62(1590):9-15. PubMed ID: 31999670
    [No Abstract]   [Full Text] [Related]  

  • 52. Pharmacology of adult ADHD with stimulants.
    Spencer TJ
    CNS Spectr; 2007 Apr; 12(4 Suppl 6):8-11. PubMed ID: 17715564
    [No Abstract]   [Full Text] [Related]  

  • 53. Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder?
    Killeen MR
    J Child Fam Nurs; 2000; 3(1):46-8. PubMed ID: 11022478
    [No Abstract]   [Full Text] [Related]  

  • 54. [Comment on the European guidelines for use of delayed action drugs for treatment of hyperkinetic disorders].
    Banaschewski T; Döpfner M; Rothenberger A; Steinhausen H-
    Z Kinder Jugendpsychiatr Psychother; 2008 Mar; 36(2):77-9. PubMed ID: 18622937
    [No Abstract]   [Full Text] [Related]  

  • 55. Cotempla XR-ODT--another long-acting methylphenidate for ADHD.
    Med Lett Drugs Ther; 2017 Nov; 59(1533):183-185. PubMed ID: 29125594
    [No Abstract]   [Full Text] [Related]  

  • 56. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Weiss M; Hechtman L; Turgay A; Jain U; Quinn D; Ahmed TS; Yates T; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
    J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):675-88. PubMed ID: 17979587
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan.
    Gau SS; Shen HY; Soong WT; Gau CS
    J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):441-55. PubMed ID: 16958569
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Managing stimulant medication for attention-deficit/hyperactivity disorder.
    Wender EH
    Pediatr Rev; 2001 Jun; 22(6):183-90. PubMed ID: 11389305
    [No Abstract]   [Full Text] [Related]  

  • 59. Long-acting methylphenidate reduces collision rates of young adult drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Davis M; Mikami AY; Singh H; Merkel RL; Burket R
    J Clin Psychopharmacol; 2012 Apr; 32(2):225-30. PubMed ID: 22367664
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Methylphenidate for attention-deficit/hyperactivity disorder: The longest debate.
    Levy F
    Aust N Z J Psychiatry; 2016 Jul; 50(7):616-7. PubMed ID: 27066820
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.